Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-11
2007-09-11
Richter, Johann (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S384000, C544S391000, C544S398000
Reexamination Certificate
active
11248618
ABSTRACT:
This invention is directed to acyl piperazine derivatives which are useful as anti-inflammatory agents. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat inflammatory disorders in humans.
REFERENCES:
patent: 3324117 (1967-06-01), Schorr et al.
patent: 4294851 (1981-10-01), Metz et al.
patent: 4439606 (1984-03-01), Du et al.
patent: 4645525 (1987-02-01), Forster et al.
patent: 4859700 (1989-08-01), Lavielle et al.
patent: 4885299 (1989-12-01), Lavielle et al.
patent: 4970301 (1990-11-01), Rolland et al.
patent: 4987132 (1991-01-01), Mase et al.
patent: 5232923 (1993-08-01), Fukazawa et al.
patent: 5272175 (1993-12-01), Hansen, Jr. et al.
patent: 5280024 (1994-01-01), Rolland et al.
patent: 5389645 (1995-02-01), Hansen, Jr. et al.
patent: 5596000 (1997-01-01), Esser et al.
patent: 5668138 (1997-09-01), Baziard-Mouysset et al.
patent: 5691340 (1997-11-01), Baziard-Mouysset et al.
patent: 6207665 (2001-03-01), Bauman et al.
patent: 6518276 (2003-02-01), Arzeno et al.
patent: 6521619 (2003-02-01), Link et al.
patent: 6528509 (2003-03-01), Hale et al.
patent: 6541476 (2003-04-01), Bauman et al.
patent: 389 112 (1987-10-01), None
patent: 260089 (1987-05-01), None
patent: 0 090 202 (1983-03-01), None
patent: 0 090 203 (1983-03-01), None
patent: 0 190 685 (1986-01-01), None
patent: 0 284 632 (1987-03-01), None
patent: 0 252 422 (1987-07-01), None
patent: 0 319 412 (1988-12-01), None
patent: 0 333 522 (1989-03-01), None
patent: 0 372 410 (1989-12-01), None
patent: 0 655 442 (1994-11-01), None
patent: 7524 (1968-03-01), None
patent: 1 434 323 (1976-05-01), None
patent: WO92/21361 (1992-12-01), None
patent: WO95/01343 (1995-01-01), None
patent: WO95/09159 (1995-04-01), None
patent: WO96/34864 (1996-11-01), None
patent: WO98/02151 (1998-01-01), None
patent: 87/02972 (1987-04-01), None
Trivedi et al. in Annual Reports in Medicinal Chemistry, vol. 35, p. 191-200 (2000).
Zikolova et al., “Analogs of N1-benzhydryl-N4-cinnamylpiperazine (oinnarizine) II N1-Substituted -N4-benzhydrylpiperazines”, Tr. Nauchnoizsled. Khim.-Farm. Inst. (1972), 8:59-67.
Ivanova et al., “Synthesis and pharmacological studies of a group of N-acylpiperazines”, Farmatsiya (Sofia) (1976), 26(4):10-14.
Nikolova et al., “Preliminary pharmacological investigation of some piperazine derivatives”, Farmatsiya (Sofia) (1969), 19(2):31-37.
Zikolova et al., “Synthesis of piperazine derivatives VI Symmetric and asymmetric N-acylpiperazines with possible biological activity”, Tr. Nauchnoizsled. Khim.-Farm. Inst. (1972), 7:109-115.
Azize et al., “Thermal behavior and elastic properties of phospholipid bilayers under the effect of a synthetic flavonoid derivative, LEW-10”, Chemistry and Physics of Lipids (1992), 63:169-177.
Carceller et al., “(Pyridylcyanomethyl) piperazines as Orally Active PAF Antagonists”, J. Med. Chem. (1992), 35:4118-4134.
Valenta et al., “Synthesis of 4-Methoxyphenoxyacetic and 3,4,5-Trimethoxyphenoxyacetic Acid Amides and Hydrazides as Potential Neurotropic and Cardiovascular Agents”, Collection Czechoslovak Chem. Commun. (1987), 52:3013-3023.
Valenta et al., “Basic Amides of 2.4.5-Trichlorophenoxyacetic, 2;4;6-Trimethylphenoxyacetic and 4-Bromo-3,5-Dimethylphenoxyacetic Acid and Some Related Compounds, Synthesis and Pharmacological Screening”, Collection Czechoslovak Chem. Commun. (1983), 48:1089-1096.
Protiva et al., “Basic Amides of 3,4,5-Trimethoxyphenoxy Acedic Acid: Synthesis and Pharmacology of Trimethophenoxamide and Analogues”, Collection Czechoslovak Chem. Commun. (1977), 42:3628-3642.
Petigara et al., “Synthesis and Central Nervous System Depressant Activity of New Piperazine and Related Derivatives III”, J. Med Chem (1969) 12(5):865-870.
Vadodaria et al., “Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives and Related Compounds II”, J. Med. Chem (1969) 12(5):860-865.
Hertz and Deghengi, “Effect of rat and beta-human interferons on hyperacute experimental allergic encephhaomyelitis in rats”, Agents Actions (1985) 16(5):397-403.
Rudick et al., “In vivo effects on interferon beta-1a on immunosuppressive cytokines in multiple schlerosis”, Neurology (1998) 50:1294-1300.
Ruuls et al., “The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats”, J. Immunol. (1996) 157:5721-5731.
Yu et al., “Interferon beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis”, J. Neuroimmunol. (1996) 64:91-100.
Rottman et al., “Central Role of CCR1+ Cells in the Immunopathogenesis of Experimental Allergic Encephalomyelitis (EAE)”, FASEB (1999) 13(5):A666 Abstract 492-16.
Protiva et al., Chemical Abstracts (1990), vol. 112, pp. 722-723, No. 158270d.
Eng et al., “Inflammation in EAE: Role of Chemokine/Cytokine Expression by Resident and Infiltrating Cells”, Neurochem. Res. (1996) 21:511-525.
Wells et al., “The Molecular Basis of the Chemokine/Chemokine Receptor Interaction—Scope for Design of Chemokine Antagonists”, Methods (1996) 10:126-134.
Leuschner, “N-Acyl substituted piperazines”, Chemical Abstracts (1974) 81:429-430, No. 136185u.
Okada and Shimabayashi, “Synthesis of N-(1-Methyl-2-piperazinoethyl)proprionanilides and 2-Alkoxy-6-[N-[1-methyl-2-2(4-phenylethylpiperazino)ethyl]-proprionamide]benzothiazoles”, Chem. Phar. Bull. (1980) 28:3315-3322.
Ransohoff et al., “Chemokines in Immune-mediated Inflammation of the Central Nervous System”, Cytokine & Growth Factor Rev. (1996) 7:35-46.
Karpus and Ransohoff, “Cutting Edge Commentary: Chemokine Regulation of Experimental Autoimmune Encephalomyelitis: Temporal and Spatial Expression Patterns Govern Disease Pathogenesis”, J. Immunol. (1998) 161:2667-2671.
Karpus et al., “An important Role for the Chemokine Macrophage Inflammatory Protein-1a in the Pathogenesis of the T Cell-Mediated Autoimmune Disease, Experimental Autoimmune Encephalomyelitis”, J. Immunol. (1995) 155:5003-5010.
Trebst et al., “CCR1+/CCR5+ Mononuclear Phagocytes Accumulate in the Central Nervous System of Patients with Multiple Sclerosis”, Am. J. Pathol. (2001) 159:1701-1710.
Rottman et al., “Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent”, Eur. J. Immunol. (2000) 30:2372-2377.
Liang et al., “Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1” J. Biol. Chem. (2000) 275:19000-19008.
Bauman John G.
Buckman Brad O.
Ghannam Ameen F.
Hesselgesser Joseph E.
Horuk Richard
Millen White Zelano & Branigan P.C.
Richter Johann
Sackey Ebenezer
Schering AG
LandOfFree
Piperazine derivatives and their use as anti-inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine derivatives and their use as anti-inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine derivatives and their use as anti-inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3756972